# US 2023/0056283 A1 · In situ solidifying solutions and methods of making and using thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0056283 A1
- Document ID: US20230056283A1
- Status: Published application
- Kind: A1
- Application number: 17/931,242
- Filed: 2022-09-12
- Published: 2023-02-23
- Earliest claimed: 2014-07-14
- Assignees: University of Utah Research Foundation
- Applicants: University of Utah Research Foundation
- Inventors: Russell J. STEWART
- Web page: https://patentgrep.com/patent/US20230056283A1

## CPC

- A61L 24/046: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds (A61L24/043 takes precedence)}
- A61K 49/0043: {Fluorescein, used in vivo}
- A61K 49/0054: {Macromolecular compounds, i.e. oligomers, polymers, dendrimers}
- A61K 49/0073: {semi-solid, gel, hydrogel, ointment}
- A61L 24/0015: {Medicaments; Biocides}
- A61L 24/0031: {Hydrogels or hydrocolloids}
- A61L 24/0042: {Materials resorbable by the body}
- A61L 24/02: containing inorganic materials
- A61L 24/043: {Mixtures of macromolecular materials}
- A61L 24/10: Polypeptides; Proteins {(A61L24/043 takes precedence)}
- A61L 24/104: {Gelatin}
- C09D 5/1668: {Vinyl-type polymers}
- A61L 2300/416: Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
- A61L 2300/44: Radioisotopes, radionuclides
- A61L 2430/02: for reconstruction of bones; weight-bearing implants
- A61L 2430/36: for embolization or occlusion, e.g. vaso-occlusive compositions or devices
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C09D: COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR (cosmetics A61K; processes for applying liquids or other fluent materials to surfaces, in general, B05D; staining wood B27K5/02; glazes or vitreous enamels C03C; natural resins, French polish, drying-oils, driers, turpentine, per se, C09F; polishing compositions other than French polish, ski waxes C09G; adhesives or use of materials as adhesives C09J; materials for sealing or packing joints or covers C09K3/10; materials for stopping leaks C09K3/12; processes for the electrolytic or electrophoretic production of coatings C25D)

## Abstract

Described herein are fluid complex coacervates that produce solid adhesives in situ. Oppositely charged polyelectrolytes were designed to form fluid adhesive complex coacervates at ionic strengths higher than the ionic strength of the application site, but an insoluble adhesive solid or gel at the application site. When the fluid, high ionic strength adhesive complex coacervates are introduced into the lower ionic strength application site, the fluid complex coacervate is converted to a an adhesive solid or gel as the salt concentration in the complex coacervate equilibrates to the application site salt concentration. In one embodiment, the fluid complex coacervates are designed to solidify in situ at physiological ionic strength and have numerous medical applications. In other aspects, the fluid complex coacervates can be used in aqueous environment for non-medical applications.

## Claims

### Claim 1

A solution comprising water, at least one polycation, at least one polyanion, and a concentration of monovalent ions in water sufficient to prevent association of the polycation and polyanion, wherein the concentration of the monovalent ions in the solution is greater than the concentration of the monovalent ions at an application site, whereupon introduction of the polyelectrolyte solution at the application site a solid or gel is produced in situ,
wherein the total positive/negative charge ratio of the polycation to the polyanion is from 4 to 0.25 and the concentration of each monovalent ion in the solution is from 0.5 M to 2.0 M.

### Claim 2 (depends on 1)

The solution of claim 1, wherein the concentration of the monovalent ions in the solution is 1.5 to 10 times greater than the concentration of the monovalent ions at the application site.

### Claim 3 (depends on 1)

The solution of claim 1, wherein the monovalent ions in the solution are sodium ions and chloride ions.

### Claim 4 (depends on 1)

The solution of claim 1, wherein the polycation comprises a biodegradable polyamine comprising a polysaccharide, a protein, a recombinant protein, a synthetic polyamine, a protamine, a branched polyamine, or an amine-modified natural polymer.

### Claim 5 (depends on 4)

The solution of claim 4, wherein the branched polyamine comprises a dendrimer having 3 to 20 arms, wherein each arm comprises a terminal amino group.

### Claim 6 (depends on 1)

The solution of claim 1, wherein the polycation comprises a polyacrylate comprising two or more pendant amino groups, wherein the amino group comprises a primary amino group, a secondary amino group, tertiary amino group, a quaternary amine, an alkylamino group, a heteroaryl group, a guanidinyl group, an imidazole, or an aromatic group substituted with one or more amino groups.

### Claim 7 (depends on 1)

The solution of claim 1, wherein the polycation comprises a polycationic micelle or a polycationic liposome.

### Claim 8 (depends on 1)

The solution of claim 1, wherein the polycation is synthetic polyguanidinyl copolymer comprising an acrylate, methacrylate, acrylamide, or methacrylamide backbone and two or more guanidinyl groups pendant to the backbone.

### Claim 9 (depends on 1)

The solution of claim 1, wherein the polyanion comprises a synthetic polymer or a naturally-occurring polymer comprising two or more carboxylate, sulfate, sulfonate, borate, boronate, phosphonate, or phosphate groups.

### Claim 10 (depends on 1)

The solution of claim 1, wherein the polyanion comprises a glycosaminoglycan or an acidic protein.

### Claim 11 (depends on 10)

The solution of claim 10, wherein the glycosaminoglycan comprises chondroitin sulfate, heparin, heparin sulfate, dermatan sulfate, keratin sulfate, or hyaluronic acid.

### Claim 12 (depends on 1)

The solution of claim 1, wherein the polyanion comprises a polymer comprising anionic groups pendant to the backbone of the polymer, incorporated in the backbone of the polymer backbone, or a combination thereof.

### Claim 13 (depends on 1)

The solution of claim 1, wherein the polyanion is a copolymer comprising two or more fragments having the formula XI
wherein R4 is hydrogen or an alkyl group;
n is from 1 to 10;
Y is oxygen, sulfur, or NR30, wherein R30 is hydrogen, an alkyl group, or an aryl group;
Z′ is carboxylate, sulfate, sulfonate, borate, boronate, a substituted or unsubstituted phosphate or phosphonate.

### Claim 14 (depends on 1)

The solution of claim 1, wherein the polyanion comprises a polyphosphate, wherein the polyphosphate comprises a natural polymer or a synthetic polymer.

### Claim 15 (depends on 14)

The solution of claim 14, wherein the polyphosphate is the copolymerization product between a phosphate acrylate and/or phosphate methacrylate with one or more additional polymerizable monomers.

### Claim 16 (depends on 1)

The solution of claim 1, wherein the polyanion has from 3-10 phosphate groups.

### Claim 17 (depends on 1)

The solution of claim 1, wherein the polyanion is an inorganic polyphosphate, a phosphorylated sugar, or a polyphosphoserine.

### Claim 18 (depends on 1)

The solution of claim 1, wherein the polyanion is inositol hexaphosphate.

### Claim 19 (depends on 1)

The solution of claim 1, wherein the polyanion comprises a hexametaphosphate salt.

### Claim 20 (depends on 1)

The solution of claim 1, wherein the polyanion is the copolymerization product between a phosphate or phosphonate acrylate or phosphate or phosphonate methacrylate with one or more additional polymerizable monomers.

### Claim 21 (depends on 1)

The solution of claim 1, wherein the solution further comprises a contrast agent or a visualization agent.

### Claim 22 (depends on 21)

The solution of claim 21, wherein the contrast agent comprises tantalum particles, gold particles, or an iodine complex.

### Claim 23 (depends on 21)

The solution of claim 21, wherein the contrast agent comprises tantalum particles having a particle size of from 0.5 μm to 50 μm and is from 10 wt % to 60 wt % of the solution.

### Claim 24 (depends on 1)

The solution of claim 1, wherein the solution further comprises a reinforcing component, wherein the reinforcing component comprises natural or synthetic fibers, water-insoluble filler particles, a nanoparticle, or a microparticle.

### Claim 25 (depends on 1)

The solution of claim 1, wherein the solution further comprises one or more bioactive agents, wherein the bioactive agent comprises an antibiotic, a pain reliever, an immune modulator, a growth factor, an enzyme inhibitor, a hormone, a messenger molecule, a cell signaling molecule, a receptor agonist, an oncolytic virus, a chemotherapy agent, a receptor antagonist, a nucleic acid, or any combination thereof.

### Claim 26 (depends on 1)

A method for producing a solid or gel in a subject in situ comprising introducing into the subject the solution of claim 1, wherein the concentration of the monovalent ions in the solution is greater than the concentration of the monovalent ions in the subject, wherein upon introduction of the solution into the subject the solution is converted to a solid or gel in situ.

### Claim 27 (depends on 26)

A method for producing a bioactive eluting depot in the subject comprising injecting into the subject the solution of claim 26.

### Claim 28 (depends on 1)

A method for reducing or inhibiting blood flow in a blood vessel of a subject comprising introducing into the vessel the solution of claim 1, wherein the concentration of the monovalent ions in the solution is greater than the concentration of the monovalent ions in the blood vessel of the subject, whereupon introduction of the solution into the vessel the solution is converted to a solid in situ within the vessel.

### Claim 29 (depends on 28)

The method of claim 28, wherein the method reduces or inhibits blood flow to a tumor, an aneurysm, a varicose vein, a vascular malformation, or a bleeding wound.

### Claim 30 (depends on 28)

The method of claim 28, wherein the method reinforces the inner wall of a blood vessel in the subject.
